siRNA-Based Carrier-Free System for Synergistic Chemo/Chemodynamic/RNAi Therapy of Drug-Resistant Tumors

Multiple drug-resistance mechanisms originate from defensive pathways in cancer and are associated with the unsatisfied efficacy of chemotherapy. The combination of small interfering RNA (siRNA) and chemotherapeutics provides a strategy for reducing drug efflux but requires more delivery options for clinical translation. Herein, multidrug resistance protein 1 (MDR1) siRNA is used as the skeleton to assemble chemotherapeutic cisplatin (CDDP) and divalent copper ion (Cu2+) for constructing a carrier-free Cu-siMDR-CDDP system. Cu-siMDR-CDDP specifically responds and disassembles in the acidic tumor microenvironment (TME). The released CDDP activates cascade bioreactions of NADPH oxidases and superoxide dismutase to generate hydrogen peroxide (H2O2). Then a Cu2+ -catalyzed Fenton-like reaction transforms H2O2 to hydroxyl radicals (HO center dot) and causes glutathione (GSH) depletion to disrupt the redox adaptation mechanism of drug-resistant cancer cells. Besides, delivery of MDR1 siRNA is facilitated by HO center dot-triggered lysosome destruction, thus inhibiting P-glycoprotein (P-gp) expression and CDDP efflux. The unique design of Cu-siMDR-CDDP is to exploit siRNA as building blocks in regulating the self-assembly behavior, and integration of functional units simultaneously alleviates limitations caused by drug- resistance mechanisms. Such a carrier-free system shows synergistic chemo/chemodynamic RNA interference therapy in suppressing tumor growth in vivo and has the reference value for overcoming drug resistance.

Automated summary

The study introduces a carrier-free Cu-siMDR-CDDP system that combines siRNA, CDDP, and Cu2+ to deactivate and release drugs in the tumor microenvironment, targeting drug-resistant cancer cell mechanisms. This system demonstrates synergistic chemo/chemodynamic RNA interference therapy in vivo.